Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules
© 2022. The Author(s), under exclusive licence to Springer Nature Limited..
BACKGROUND: Bronchial washing fluid (BWF) is a less-invasive specimen. Due to the limited sensitivity of BWF cellular component diagnosis, the aim of this study was to explore the potential role of BWF supernatant as a source of liquid biopsy of lung cancer.
METHODS: This prospective study enrolled 76 suspected and 5 progressed lung cancer patients. Transbronchial biopsy tissues, BWF supernatant (BWF_Sup) and BWF precipitant (BWF_Pre) were tested by a targeted panel of 1021 genes.
RESULTS: BWF_Sup cell-free DNA (cfDNA) was superior to tissue biopsy and BWF_Pre in determining mutational allele frequency, tumour mutational burden, and chromosomal instability. Moreover, BWF_Sup and BWF_Pre achieved comparable efficacy to tissue samples in differentiating malignant and benign patients, but only BWF_Sup persisted differentiated performance after excluding 55 malignancies pathologically diagnosed by bronchoscopic biopsy. Among 67 malignant patients, 82.1% and 71.6% of tumour-derived mutations (TDMs) were detected in BWF_Sup and BWF_Pre, respectively, and the detectability of TDMs in BWF_Sup was independent of the cytological examination of BWF. BWF_Sup outperformed BWF_Pre in providing more subclonal information and thus might yield advantage in tracking drug-resistant markers.
CONCLUSIONS: BWF_Sup cfDNA is a reliable medium for lung cancer diagnosis and genomic profiles and may provide important information for subsequent therapeutic regimens.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:127 |
|---|---|
| Enthalten in: |
British journal of cancer - 127(2022), 12 vom: 17. Dez., Seite 2154-2165 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhang, Xinyu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 15.12.2022 Date Revised 18.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41416-022-01969-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347684106 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347684106 | ||
| 003 | DE-627 | ||
| 005 | 20231226034420.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41416-022-01969-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1158.xml |
| 035 | |a (DE-627)NLM347684106 | ||
| 035 | |a (NLM)36253524 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhang, Xinyu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Utility of cell-free DNA from bronchial washing fluid in diagnosis and genomic determination for radiology-suspected pulmonary nodules |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2022 | ||
| 500 | |a Date Revised 18.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a BACKGROUND: Bronchial washing fluid (BWF) is a less-invasive specimen. Due to the limited sensitivity of BWF cellular component diagnosis, the aim of this study was to explore the potential role of BWF supernatant as a source of liquid biopsy of lung cancer | ||
| 520 | |a METHODS: This prospective study enrolled 76 suspected and 5 progressed lung cancer patients. Transbronchial biopsy tissues, BWF supernatant (BWF_Sup) and BWF precipitant (BWF_Pre) were tested by a targeted panel of 1021 genes | ||
| 520 | |a RESULTS: BWF_Sup cell-free DNA (cfDNA) was superior to tissue biopsy and BWF_Pre in determining mutational allele frequency, tumour mutational burden, and chromosomal instability. Moreover, BWF_Sup and BWF_Pre achieved comparable efficacy to tissue samples in differentiating malignant and benign patients, but only BWF_Sup persisted differentiated performance after excluding 55 malignancies pathologically diagnosed by bronchoscopic biopsy. Among 67 malignant patients, 82.1% and 71.6% of tumour-derived mutations (TDMs) were detected in BWF_Sup and BWF_Pre, respectively, and the detectability of TDMs in BWF_Sup was independent of the cytological examination of BWF. BWF_Sup outperformed BWF_Pre in providing more subclonal information and thus might yield advantage in tracking drug-resistant markers | ||
| 520 | |a CONCLUSIONS: BWF_Sup cfDNA is a reliable medium for lung cancer diagnosis and genomic profiles and may provide important information for subsequent therapeutic regimens | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cell-Free Nucleic Acids |2 NLM | |
| 700 | 1 | |a Yu, Zhuo |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Yaping |e verfasserin |4 aut | |
| 700 | 1 | |a Chao, Yencheng |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Qin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Maosong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Xiuli |e verfasserin |4 aut | |
| 700 | 1 | |a Cui, Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Yuhua |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Yanfang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Min |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jian'an |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Kai |e verfasserin |4 aut | |
| 700 | 1 | |a Hou, Yingyong |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Xuefeng |e verfasserin |4 aut | |
| 700 | 1 | |a Pu, Xingxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Carbone, David P |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of cancer |d 1947 |g 127(2022), 12 vom: 17. Dez., Seite 2154-2165 |w (DE-627)NLM000027537 |x 1532-1827 |7 nnns |
| 773 | 1 | 8 | |g volume:127 |g year:2022 |g number:12 |g day:17 |g month:12 |g pages:2154-2165 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41416-022-01969-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 127 |j 2022 |e 12 |b 17 |c 12 |h 2154-2165 | ||